IHS Chemical Week

Regions :: Western Europe :: Germany

Merck KGaA terminates license agreement with Japanese pharma producer

2:26 AM MDT | June 17, 2014 | Natasha Alperowicz

Merck KGaA announced today that it has reached a mutual agreement with Ono Pharmaceutical (Osaka) to terminate a license agreement for ceralifimod (ONO-4641) because it does not meet Merck’s threshold for continued investment. Merck obtained the worldwide, exclusive license rights from Ono Pharmaceutical for the development and commercialization of ONO-4641 in multiple sclerosis (MS) outside of Japan, Korea, and Taiwan in October 2011. The drug candidate is currently in phase-two clinical development.   Merck says its biopharmaceutical division, Merck...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa